Pain

Areas of Partnering Interest

• Novel proprietary targets for neuropathic and OA pain
• Neuropathic and inflammatory therapies in Phases 1, 2, or 3
• New formulations of marketed drugs if they provide the opportunity for rapid revenues
• Cannabinoid agonists in Phase 2 with proven clinical efficacy and safety
• Agents targeting the opioid pathway with demonstrated lower abuse liability by virtue of formulation, delivery system, or pharmacokinetics (PK)
• Selective sodium channel modulators
• Potassium channel openers
• Calcium, sub-type selective modulators
• Acid Sensing Ion Channel (ASIC) blockers
• Transient Receptor Potential (TRP) channel blockers, particularly TRPV3, V4, M8, A1
• Biomarkers and genetic markers of chronic pain
• Improved chronic pain models
• P2X antagonists
• Novel approaches to understanding neurochemistry of pain processing
• Novel electrophysiology, including multiunit recording techniques or telemetry, automated single-cell screening methodologies
• Mathematical modeling techniques for analysis of neural activity
• Novel delivery systems for target evaluation
• Glia and astrocytic activation and cell biology
• Any clinical genomics data showing mutations with a linkage to alterations in pain processing
• Topical preparations including local anaesthetics
• Novel formulations for acute pain (post-operative pain) as a stand-alone indication

• Back to Areas of Interest

Jim Kenney
Submit your idea